Qpex Biopharma

Executive Summary

Qpex Biopharma is a clinical-stage biopharmaceutical company dedicated to combating antimicrobial resistance (AMR) through the development of novel anti-infective therapies. As a Shionogi Group company, Qpex leverages strategic partnerships and deep expertise in small molecules to advance a pipeline of next-generation antibiotics and non-antibiotic adjuvants targeting drug-resistant bacterial and fungal pathogens. The company's lead programs focus on Gram-negative bacteria, including Acinetobacter baumannii and Pseudomonas aeruginosa, areas of high unmet medical need. Qpex's platform includes novel beta-lactamase inhibitors and antibiotic-adjuvant combinations designed to restore the efficacy of existing antibiotics. With a strong foundation in preclinical and clinical development, the company is positioned to address the global public health threat of AMR. Qpex is advancing its lead candidate, a beta-lactamase inhibitor combination, through clinical trials. Key upcoming milestones include the readout of Phase 2 data for this program, which could validate the platform and support progression to Phase 3. The company is also exploring additional indications and adjuvant combinations. With support from Shionogi and a focused strategy on AMR, Qpex has the potential to deliver innovative treatments to patients. The conviction score reflects the company's strong scientific rationale, strategic backing, and clear clinical path, tempered by the inherent risks of clinical development and competitive landscape.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Data Readout for Lead Beta-Lactamase Inhibitor Combination55% success
• Q4 2026Initiation of Phase 3 Trial for Lead Candidate45% success
• TBDPreclinical Data for Novel Non-Antibiotic Adjuvant40% success